Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.

Kawamoto K, Suzuki T, Kasami T, Kiryu M, Sone H, Miyoshi H, Ohshima K, Takizawa J.

Hematol Oncol. 2018 Nov 5. doi: 10.1002/hon.2565. [Epub ahead of print] No abstract available.

PMID:
30394560
2.

Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report.

Tamura S, Kawamoto K, Miyoshi H, Suzuki T, Katagiri T, Kasami T, Nemoto H, Miyakoshi S, Kobayashi H, Shibasaki Y, Masuko M, Takeuchi K, Ohshima K, Sone H, Takizawa J.

J Clin Exp Hematop. 2018 Dec 13;58(4):161-165. doi: 10.3960/jslrt.18015. Epub 2018 Oct 10.

3.

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.

Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Tamura S, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J.

Intern Med. 2019 Feb 15;58(4):575-580. doi: 10.2169/internalmedicine.1686-18. Epub 2018 Sep 12.

4.

Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.

Itamura H, Ide M, Sato A, Sueoka-Aragane N, Sueoka E, Nishida A, Masunari T, Aoki S, Takizawa J, Suzumiya J, Kimura S.

Int J Hematol. 2018 Oct;108(4):416-422. doi: 10.1007/s12185-018-2506-3. Epub 2018 Jul 24.

PMID:
30043333
5.

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.

Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S, Tsuyama N, Dobashi A, Sasaki M, Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K.

Leukemia. 2018 Dec;32(12):2590-2603. doi: 10.1038/s41375-018-0154-5. Epub 2018 May 23.

PMID:
29795241
6.

Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.

Kawamoto K, Miyoshi H, Suzuki T, Kiyasu J, Yokoyama S, Sasaki Y, Sone H, Seto M, Takizawa J, Ohshima K.

Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2506. [Epub ahead of print]

PMID:
29602174
7.

[Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity].

Tanaka T, Kozakai T, Kitajima T, Fuse K, Kobayashi H, Ushiki T, Shibazaki Y, Moriyama M, Takizawa J, Sone H, Fuse I, Masuko M.

Rinsho Ketsueki. 2017;58(12):2402-2405. doi: 10.11406/rinketsu.58.2402. Japanese.

PMID:
29332874
8.

A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features.

Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, Kato K, Miyahara M, Yujiri T, Choi I, Fujimaki K, Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K.

Haematologica. 2018 Jun;103(6):1018-1028. doi: 10.3324/haematol.2017.174177. Epub 2017 Dec 14.

9.

Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.

Kawamoto K, Miyoshi H, Suzuki T, Sasaki Y, Yamada K, Yanagida E, Muto R, Kiryu M, Sone H, Seto M, Ohshima K, Takizawa J.

Hematol Oncol. 2018 Feb;36(1):166-173. doi: 10.1002/hon.2482. Epub 2017 Oct 20.

PMID:
29052238
10.

MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia.

Kozakai T, Takahashi M, Higuchi M, Hara T, Saito K, Tanaka Y, Masuko M, Takizawa J, Sone H, Fujii M.

Int J Hematol. 2018 Mar;107(3):337-344. doi: 10.1007/s12185-017-2359-1. Epub 2017 Oct 17.

PMID:
29043551
11.

Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Miyaoka M, Kikuti YY, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose T, Sakai R, Hoshikawa M, Tomita N, Miura I, Takata K, Yoshino T, Takizawa J, Bea S, Campo E, Nakamura N.

Mod Pathol. 2018 Feb;31(2):313-326. doi: 10.1038/modpathol.2017.134. Epub 2017 Oct 6.

12.

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review.

Katagiri T, Ushiki T, Masuko M, Tanaka T, Miyakoshi S, Fuse K, Shibasaki Y, Takizawa J, Aoki S, Sone H.

Medicine (Baltimore). 2017 Sep;96(36):e7975. doi: 10.1097/MD.0000000000007975. Review.

13.

Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis.

Suzuki T, Kawamoto K, Tamura S, Uemura S, Kaihatsu A, Nemoto H, Kobayashi H, Ushiki T, Fuse K, Shibazaki Y, Moriyama M, Masuko M, Narita M, Sone H, Aoki S, Nakamura N, Oshima K, Takizawa J.

Rinsho Ketsueki. 2017;58(8):905-911. doi: 10.11406/rinketsu.58.905. Japanese.

PMID:
28883272
14.

Chronic lymphocytic leukemia: pathophysiology and current therapy.

Takizawa J.

Rinsho Ketsueki. 2017;58(5):471-479. doi: 10.11406/rinketsu.58.471. Japanese.

PMID:
28592762
15.

Clinicopathological features of cryptococcal lymphadenitis and a review of literature.

Kawamoto K, Miyoshi H, Suzuki T, Muto R, Yamada K, Yanagida E, Koshino M, Sasaki Y, Takizawa J, Sone H, Sugita Y, Seto M, Ohshima K.

J Clin Exp Hematop. 2017 Jul 5;57(1):26-30. doi: 10.3960/jslrt.17011. Epub 2017 Jun 8. Review.

16.

A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.

Miura K, Konishi J, Miyake T, Makita M, Hojo A, Masaki Y, Uno M, Ozaki J, Yoshida C, Niiya D, Kitazume K, Maeda Y, Takizawa J, Sakai R, Yano T, Yamamoto K, Sunami K, Hiramatsu Y, Aoyama K, Tsujimura H, Murakami J, Hatta Y, Kanno M.

Oncologist. 2017 May;22(5):554-560. doi: 10.1634/theoncologist.2016-0260. Epub 2017 Apr 13.

17.

Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy.

Suwabe T, Shibasaki Y, Kaihatsu A, Katagiri T, Miyakoshi S, Fuse K, Kobayashi H, Ushiki T, Moriyama M, Takizawa J, Narita M, Sone H, Masuko M.

Rinsho Ketsueki. 2017;58(1):32-36. doi: 10.11406/rinketsu.58.32. Japanese.

PMID:
28190863
18.

Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.

Kawamoto K, Miyoshi H, Yanagida E, Yoshida N, Kiyasu J, Kozai Y, Morikita T, Kato T, Suzushima H, Tamura S, Muta T, Kato K, Eto T, Seki R, Nagafuji K, Sone H, Takizawa J, Seto M, Ohshima K.

Eur J Haematol. 2017 May;98(5):459-466. doi: 10.1111/ejh.12856. Epub 2017 Mar 3.

PMID:
28129454
19.

Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.

Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, Maeda T, Itasaka S, Kubota N, Saito Y, Kobayashi Y, Itami J, Ueda K, Miyazaki K, Ii N, Tomita N, Sekiguchi N, Takizawa J, Saito B, Murayama T, Ando T, Wada H, Hyo R, Ejima Y, Hasegawa M, Katayama N.

J Clin Oncol. 2017 Jan;35(1):32-39. Epub 2016 Oct 31.

PMID:
28034070
20.

Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients.

Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K.

Am J Surg Pathol. 2016 Nov;40(11):1473-1483.

PMID:
27631510
21.

The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.

Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J.

Leuk Lymphoma. 2016 Dec;57(12):2763-2770. Epub 2016 Jun 20.

PMID:
27320054
22.

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.

Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H, Takizawa J.

Cancer Sci. 2016 Jun;107(6):853-61. doi: 10.1111/cas.12942. Epub 2016 May 6.

23.

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma.

Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, Takizawa J, Mitani K, Igarashi T, Sakai K, Miyazaki K, Mihara K, Ohmachi K, Nakamura N, Takasaki H, Kiyoi H, Nakamura S, Kinoshita T, Ogura M.

Blood Cancer J. 2015 Dec 4;5:e372. doi: 10.1038/bcj.2015.101. No abstract available.

24.

Versatile Molding Process for Tough Cellulose Hydrogel Materials.

Kimura M, Shinohara Y, Takizawa J, Ren S, Sagisaka K, Lin Y, Hattori Y, Hinestroza JP.

Sci Rep. 2015 Nov 5;5:16266. doi: 10.1038/srep16266.

25.

Fatal tracheal aspergillosis during rituximab combined chemotherapy for diffuse large B-cell lymphoma that developed after lung transplantation.

Kawamoto K, Shibasaki Y, Sato S, Nemoto H, Takizawa J, Narita M, Tsuchida M, Sone H, Masuko M.

Transpl Infect Dis. 2015 Dec;17(6):872-5. doi: 10.1111/tid.12458. Epub 2015 Nov 13.

PMID:
26369902
26.

Possible Involvement of Lung Cells Harboring an Abnormal Karyotype in the Pathogenesis of Pulmonary Alveolar Proteinosis Associated with Myelodysplastic Syndrome.

Moriyama M, Yano T, Furukawa T, Takada T, Ushiki T, Masuko M, Takizawa J, Sone H, Tazawa R, Saijo Y, Ishii H, Nakata K.

Ann Am Thorac Soc. 2015 Aug;12(8):1251-3. doi: 10.1513/AnnalsATS.201503-175LE. No abstract available.

PMID:
26317278
27.

Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.

Iwabuchi M, Narita M, Uchiyama T, Iwaya S, Oiwa E, Nishizawa Y, Hashimoto S, Bonehill A, Kasahara N, Takizawa J, Takahashi M.

Mol Med Rep. 2015 Aug;12(2):2443-50. doi: 10.3892/mmr.2015.3685. Epub 2015 Apr 24.

28.

The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients.

Shibasaki Y, Seki Y, Tanaka T, Miyakoshi S, Fuse K, Kozakai T, Kobayashi H, Ushiki T, Abe T, Yano T, Moriyama M, Kuroha T, Isahai N, Takizawa J, Narita M, Koyama S, Furukawa T, Sone H, Masuko M.

Leuk Res. 2015 Jun;39(6):667-71. doi: 10.1016/j.leukres.2015.03.021. Epub 2015 Apr 7.

PMID:
25890432
29.

Late onset post-transfusion hepatitis E developing during chemotherapy for acute promyelocytic leukemia.

Fuse K, Matsuyama Y, Moriyama M, Miyakoshi S, Shibasaki Y, Takizawa J, Furukawa T, Fuse I, Matsumura H, Uchida S, Takahashi Y, Kamimura K, Abe H, Suda T, Aoyagi Y, Sone H, Masuko M.

Intern Med. 2015;54(6):657-61. doi: 10.2169/internalmedicine.54.2332. Epub 2015 Jan 15.

30.
31.

Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.

Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Igarashi T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura M.

Haematologica. 2014 Dec;99(12):1817-25. doi: 10.3324/haematol.2014.111203. Epub 2014 Sep 12.

32.

Activation of the leukemia plasmacytoid dendritic cell line PMDC05 by Toho-1, a novel IDO inhibitor.

Yamahira A, Narita M, Iwabuchi M, Uchiyama T, Iwaya S, Ohiwa R, Nishizawa Y, Suzuki T, Yokoyama Y, Hashimoto S, Takizawa J, Sone H, Takahashi M.

Anticancer Res. 2014 Aug;34(8):4021-8.

PMID:
25075025
33.

Early diagnosis of hepatic intravascular lymphoma: a case report and literature review.

Abe H, Kamimura K, Mamizu M, Shibazaki Y, Ishiguro T, Katada S, Nishiyama YK, Takahashi Y, Hatano YY, Mizuno K, Watanabe Y, Nagashima A, Takizawa J, Takeuchi M, Kawai H, Nomoto M, Sone H, Nishizawa M, Aoyagi Y.

Intern Med. 2014;53(6):587-93. Review.

34.

Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.

Kato H, Karube K, Yamamoto K, Takizawa J, Tsuzuki S, Yatabe Y, Kanda T, Katayama M, Ozawa Y, Ishitsuka K, Okamoto M, Kinoshita T, Ohshima K, Nakamura S, Morishima Y, Seto M.

Cancer Sci. 2014 May;105(5):537-44. doi: 10.1111/cas.12389. Epub 2014 Apr 9.

35.

Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine.

Okazuka K, Masuko M, Matsuo Y, Miyakoshi S, Tanaka T, Kozakai T, Kobayashi H, Fuse K, Shibasaki Y, Moriyama M, Takizawa J, Fuse I, Toba K, Furukawa T.

Intern Med. 2013;52(11):1239-42.

36.

MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.

Kojima M, Nishikii H, Takizawa J, Aoki S, Noguchi M, Chiba S, Ando K, Nakamura N.

Leuk Lymphoma. 2013 Oct;54(10):2149-54. doi: 10.3109/10428194.2013.771398. Epub 2013 Mar 8.

PMID:
23363269
37.

Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphoma.

Ogura R, Aoki H, Natsumeda M, Shimizu H, Kobayashi T, Saito T, Takizawa J, Okamoto K, Hasegawa G, Umezu H, Ohshima K, Takahashi H, Fujii Y, Kakita A.

Neuropathology. 2013 Aug;33(4):436-41. doi: 10.1111/neup.12005. Epub 2012 Dec 21.

PMID:
23279449
38.

Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene.

Yamahira A, Narita M, Ishii K, Jayathilake RM, Iwabuchi M, Satoh N, Uchiyama T, Taniguchi T, Hashimoto S, Kasahara N, Faure E, Bogan B, Takizawa J, Sone H, Takahashi M.

Leuk Res. 2012 Dec;36(12):1541-6. doi: 10.1016/j.leukres.2012.09.002. Epub 2012 Oct 3.

PMID:
23040531
39.

Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.

Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R.

Clin Cancer Res. 2012 Aug 1;18(15):4183-90. Epub 2012 Jun 6.

40.

IgM-type GM-CSF autoantibody is etiologically a bystander but associated with IgG-type autoantibody production in autoimmune pulmonary alveolar proteinosis.

Nei T, Urano S, Motoi N, Takizawa J, Kaneko C, Kanazawa H, Tazawa R, Nakagaki K, Akagawa KS, Akasaka K, Ichiwata T, Azuma A, Nakata K.

Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L959-64. doi: 10.1152/ajplung.00378.2011. Epub 2012 Feb 24.

41.

Multifocal mucosa-associated lymphoid tissue lymphoma associated with IgG4-related disease: a case report.

Oyama T, Takizawa J, Nakamura N, Aoki S, Aizawa Y, Abe H.

Jpn J Ophthalmol. 2011 May;55(3):304-306. doi: 10.1007/s10384-011-0003-9. Epub 2011 May 17. No abstract available.

PMID:
21584726
42.

Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan.

Miura K, Takasaki H, Tsujimura H, Kanno M, Maeda Y, Tomita N, Takai K, Masaki Y, Takizawa J, Mori H, Terasaki Y, Yoshida T, Takeuchi J, Motomura S.

Int J Hematol. 2011 May;93(5):684-686. doi: 10.1007/s12185-011-0845-4. Epub 2011 Apr 12. No abstract available.

PMID:
21479980
43.

Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.

Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M.

Blood. 2010 Dec 9;116(24):5119-25. doi: 10.1182/blood-2010-06-289231. Epub 2010 Sep 7.

44.

Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation.

Furukawa T, Kurasaki-Ida T, Masuko M, Tsukada N, Okazuka K, Sato N, Yano T, Abe T, Momoi A, Shibasaki Y, Higashimura M, Karimata K, Moriyama M, Kuroha T, Takizawa J, Toba K, Narita M, Fuse I, Takahashi M, Aizawa Y.

Int J Hematol. 2010 Jul;92(1):144-51. doi: 10.1007/s12185-010-0610-0. Epub 2010 Jun 9.

PMID:
20533008
45.

[Prevention of phlebitis caused by vinorelbine chemotherapy in outpatients with breast cancer].

Yokota Y, Suzuki T, Narahashi T, Takizawa J, Kojima M, Shimada R.

Gan To Kagaku Ryoho. 2008 Sep;35(9):1525-9. Japanese.

PMID:
18799905
46.

Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system.

Li J, Okamoto H, Yin C, Jagannathan J, Takizawa J, Aoki S, Gläsker S, Rushing EJ, Vortmeyer AO, Oldfield EH, Yamanaka R, Zhuang Z.

J Neurosurg. 2008 Sep;109(3):536-46. doi: 10.3171/JNS/2008/109/9/0536.

PMID:
18759588
47.

Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.

Saitoh A, Narita M, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Aizawa Y, Shinada S, Takahashi M.

Med Oncol. 2008;25(2):137-47. doi: 10.1007/s12032-007-9004-4. Epub 2007 Sep 11.

PMID:
18488155
48.

Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells.

Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Fuse I, Aizawa Y, Shinada S, Takahashi M.

J Clin Exp Hematop. 2007 Nov;47(2):61-72. Erratum in: J Clin Exp Hematop. 2008 Apr;48(1):33.

49.

Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation.

Takizawa J, Aoki S, Kurasaki T, Higashimura M, Honma K, Kitajima T, Momoi A, Takahashi H, Nakamura N, Furukawa T, Aizawa Y.

Am J Hematol. 2007 Dec;82(12):1113-5.

50.

Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients.

Takahashi H, Furukawa T, Yano T, Sato N, Takizawa J, Kurasaki T, Abe T, Narita M, Masuko M, Koyama S, Toba K, Takahashi M, Aizawa Y.

Exp Hematol. 2007 Jul;35(7):1091-9.

PMID:
17588478

Supplemental Content

Loading ...
Support Center